[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].

Autor:	Lebedkina MS; City Clinical Hospital №52, Moscow., Fomina DS; City Clinical Hospital №52, Moscow.; Sechenov First Moscow State Medical University (Sechenov University)., Mutovina ZY; City Clinical Hospital №52, Moscow.; Central State Medical Academy of the President of the Russian Federation., Mаrkina UA; City Clinical Hospital №52, Moscow., Bogomolov PO; Vladimirsky Moscow Regional Research Clinical Institute.; Yevdokimov Moscow State University of Medicine and Dentistry., Chulanov VP; Sechenov First Moscow State Medical University (Sechenov University).; National Medical Research Center of Tuberculosis and Infectious Diseases., Lysenko MA; City Clinical Hospital №52, Moscow.; Pirogov Russian National Research Medical University., Alexeeva EI; Sechenov First Moscow State Medical University (Sechenov University).; National Medical Research Center for Children's Health.
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2023 Aug 17; Vol. 95 (6), pp. 494-499. Date of Electronic Publication: 2023 Aug 17.
DOI:	10.26442/00403660.2023.06.202297
Abstrakt:	Aim: To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies - MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and Methods: A non-interventional non-comparative observational study with primary prospective data collection included 108 patients with mild to moderate COVID-19 (mean age 61 years), who had risk factors for developing severe disease. All patients ( n =108) were treated with a combination of MAB casirivimab and imdevimab intravenous single infusion 1200 mg (600 mg of each component). The efficacy and safety of MAB were assessed at 7, 14, and 28 days after infusion. Results: Efficacy. Indications for hospitalization by day 7 from the moment of MAB administration were in 0.9% ( n =1), by day 14 - in 1.9% ( n =2), by day 28 - in 0.9% of patients; to stay in the intensive care units by the 7th day - in 4.6% ( n =5), by the 14th day - in 0.9% ( n =1), by the 28th day - in 0.9% ( n =1) patients. During 28 days of follow up, the need for mechanical ventilation and extracorporeal membrane oxygenation was registered in 2/108 (1.8%) patients. There were no deaths directly related to COVID-19 in the assessed cohort of patients. Safety. By the 28th day of the follow up, no adverse effects due to MAB therapy were registered. Conclusion: An analysis of the results of a non-interventional observational study summarized in this article showed the high efficacy and safety of virus-neutralizing MAB combination (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with of risk factors for severe COVID-19 in real word settings.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu